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Abstract
Incomplete Freund's adjuvant (IFA) serves as a carrier for water-in-oil emulsion (W/O) vaccines.
The stability of such emulsions greatly affects vaccine safety and efficacy since continued presence
of antigen depots at lymphoid organs releasing low-level antigens is known to stimulate a potent
immune response and high-level systemic release of antigens can lead to tolerance. W/O emulsions
for the purpose of clinical and laboratory peptide-based vaccinations have been prepared using the
techniques of syringe extrusion, vortex or high-speed homogenization. There is no consensus in
the field over which technique would be best to use and no immunological data are available that
compare the three techniques. In this study, we compared the immune responses induced by a
peptide-based vaccine prepared using vortex, syringe-extrusion and homogenization. The
vaccination led to tumor rejection by mice vaccinated with the peptide-based vaccine prepared
using all three techniques. The immunological data from the in vivo cytotoxicity assay showed a
trend for lower responses and a higher variability and greater range in the immune responses
induced by a vaccine that was emulsified by the vortex or homogenizer techniques as compared to
the syringe-extrusion technique. There were statistically significant lower numbers of IFNγ-
secreting cells induced when the mice were vaccinated with a peptide-based vaccine emulsion
prepared using the vortex compared to the syringe-extrusion technique. At a suboptimal vaccine
dose, the mice vaccinated with a peptide-based vaccine emulsion prepared using the vortex
technique had the largest tumors compared to the syringe-extrusion or the homogenizer
technique. In the setting of a busy pharmacy that prepares peptide-based vaccine emulsions for
clinical studies, the vortex technique can still be used but we urge investigators to take special care
in their choice of mixing vessels for the vortex technique as that can influence the stability of the
emulsion. However, in instances where the optimal dose is unknown, we caution investigators
against using the vortex technique to prepare the peptide-based vaccine emulsions. Overall, we
report that all three techniques can be used to prepare peptide-based vaccine emulsions under
optimal dose conditions and we discuss important details regarding the proper preparation of the
emulsions.
Published: 23 October 2006
Journal of Translational Medicine 2006, 4:42 doi:10.1186/1479-5876-4-42
Received: 30 August 2006
Accepted: 23 October 2006
This article is available from: http://www.translational-medicine.com/content/4/1/42
© 2006 Koh et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
Page 2 of 12
(page number not for citation purposes)
Background
Adjuvants augment and potentiate immunological
responses and have been used to increase the efficacy of
vaccines. Mineral oils were first used as an adjuvant in
1916 when Le Moignic and Pinoy found that a suspension
of killed Salmonella typhimurium in vaseline oil with lano-
lin as an emulsifier increased immune responses[1]. Two
decades later, Jules Freund developed a potent adjuvant,
Freund's complete adjuvant (FCA) which was basically a
mineral (paraffin) oil containing killed mycobacteria.
FCA was developed in the mid-1930s following the obser-
vation that guinea pigs infected with Mycobacterium tuber-
culosis produced higher titer antibody responses following
immunization than non-infected animals[2]. Freund later
found that immunization of the protein antigen in a
water-in-paraffin oil emulsion without killed mycobacte-
ria was just as effective in increasing and prolonging anti-
body formation[3], leading to the development of
incomplete Freund's adjuvant (IFA) which is a water-in-
oil (W/O) emulsion without killed mycobacteria.
Although FCA is one of the most effective adjuvants
known, it results in generalized granulomatous prolifera-
tion in various organs [4-6], severe pain and distress[7]
and is not approved for human use. The prototypical FCA
and IFA contained impurities in the crude mineral oil that
led to the reports of site-of-injection toxicities [8-10].
Since then, efforts aimed at increasing the adjuvant
potency of IFA while reducing toxicity have led to new
generations of highly purified mineral oils such as the
Montanide incomplete Seppic adjuvants (ISAs) (Seppic,
Paris, France) that have been approved for both human
and veterinary use[11,12]. IFA types of adjuvants such as
Montanide ISA-51 and Montanide ISA-720 are now
widely used in cancer immunotherapy strategies in
patients[13,14] and can be combined with other adju-
vants such as immunostimulatory CpG oligodeoxynucle-
otides[15] that trigger the innate immune response
through Toll-like receptors.
An emulsion is a thermodynamically unstable mixture of
two immiscible liquids. The peptide IFA W/O emulsions
consist of the peptide antigen dissolved in the phosphate
buffered saline (PBS) liquid phase dispersed in the min-
eral oil phase. A well-prepared IFA emulsion is a thick, vis-
cous, white mixture that does not disperse when dropped
into a beaker of water. This property of the emulsion
allows it to maintain an antigen depot that does not dis-
perse readily into the aqueous environment protecting the
peptide antigen from rapid degradation. The integrity of
emulsions is classically determined by a water-drop test
where a small drop of emulsion is placed on the surface of
room temperature distilled water[16]. The emulsion has
to be mixed to a point where an emulsion droplet does
not fall apart upon contact with the water and form an
oily slick over the surface of the water. When the IFA W/O
emulsion falls apart, antigen is released into the system.
The kinetics of antigen release has been shown to deter-
mine the level of immune response in murine models
[17-19]. Generally, the regulated slow release of antigen
into the host stimulates an immunogenic response while
a rapid systemic distribution of antigen can lead to the
induction of T cell tolerance [17-19]. The integrity of W/O
emulsions is important because the large multimolecular
emulsion aggregates can promote uptake by macrophages
and dendritic cells, facilitating their transport into the
lymphatics where the localized small depots of antigens
persist to stimulate the immune response[20,21].
This paper aims to compare the immune responses
induced by a peptide-based vaccine prepared using one of
the three emulsification techniques (syringe-extrusion,
the vortex and the homogenizer) and to give advice to
investigators in the field on the best technique to use. In
the conventional syringe-extrusion technique[22], the
aqueous phase containing the antigen is forced into an
equal volume of the oil-phase adjuvant either through
double-hubbed small-bore needles or three-way stop-
cocks[16,23]. The vortex method[24] is simple and has
been used to prepare veterinary and human vaccines[25].
The water phase and the mineral oil phase is placed in the
same tube and mixed by vortexing until an emulsion is
formed[26]. Industrially, W/O emulsions are prepared
using high-speed homogenization[27]. We have success-
fully used the homogenizer technique to prepare W/O
emulsions that have been used to induce immune
responses in mice[17] and we will now compare the level
of immune responses induced by peptide emulsions vac-
cines prepared using the syringe-extrusion, the vortex and
the homogenizer techniques. The conventional syringe-
extrusion technique is probably the most commonly used
technique, but is very tedious and laborious. Although W/
O emulsions have been prepared in clinical trials by vor-
texing on a table-top vortex and used for cancer immuno-
therapy of patients[13,28], there is a debate within the
field about the quality of emulsions prepared using the
vortex versus syringe-extrusion techniques. The syringe-
extrusion method is thought to be superior to the vortex
because the emulsions obtained appear to be more vis-
cous. The homogenizer uses high-speed shear force to
emulsify the W/O emulsion, is convenient and produces
an emulsion of equal or greater apparent viscosity com-
pared to the syringe-extrusion method. The homogenizer
is a more expensive piece of equipment compared to the
glass syringes used in the syringe-extrusion technique or
to the vortex and is therefore less commonly used com-
pared to the other two.Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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Materials and methods
The C3 cell line is a tumorigenic human papilloma virus
(HPV) 16 and EJ-ras transformed C57BL/6 mouse embryo
cell that expresses the E7 early protein[29]. The C3 cell
line was maintained in Iscove's Modified Dulbecco's
Medium (IMDM) supplemented with 10% heat-inacti-
vated fetal calf serum, 2 mM l-glutamine (Gibco-Invitro-
gen, Carlsbad, CA), 50 mM 2-mercaptoethanol (EMD
Chemicals, Gibbstown, NJ) and 100 µg/ml of kanamycin
(Sigma-Aldrich, St. Louis, MO). Cells were incubated at
37°C, 5% CO2. All peptides were synthesized by the
Microchemistry core facility of the Norris Comprehensive
Cancer Center or provided by Dr. Steve Meredith of the
University of Chicago. HPV-16 E7 peptide
(RAHYNIVTF49-57) is a H-2Db-binding peptide that medi-
ates rejection of C3 tumors in C57BL/6 mice[29]. The
prostate-specific antigen PSA peptide (VTWIGAAPL (-3)-6)
binds to both H-2Db and H-2Kb (unpublished results) and
was used as an irrelevant peptide control for the immune
assays.
Peptide emulsion preparation
100 mg/ml HPV 16 E7 peptide stocks were dissolved in
dimethylsufoxide (DMSO) and stored as 1 mg aliquots at
-80°C. HPV 16 E7 peptide was dissolved in PBS at 2 mg/
ml and emulsified at a 1:1 ratio with incomplete Freund's
adjuvant (IFA) (Rockland Immunologicals, Gilbertsville,
PA) to obtain a final concentration of 1 mg/ml. To prepare
the emulsion by vortexing, the PBS-IFA mixture was
placed in 1.7 ml or 2 ml Eppendorf tubes, taped flat down
on the vortex head (VWR, West Chester, PA) and vortexed
for ten minutes at a maximum speed of 3, 200 rpm (Fig.
1a). Emulsification by syringe-extrusion was carried out
by passing the PBS-IFA mixture through a reinforced 22-
gauge connector between two glass syringes for ten min-
utes (Fig. 1b). Emulsion preparation by homogenizer was
achieved using the polytron PT2100 (Kinematica AG, Lit-
tau-Lucerne, Switzerland) (Fig. 1c). The integrity of the
emulsions were tested using the water-drop method and
were deemed properly emulsified when they did not dis-
perse immediately after a droplet was dropped into a
beaker of water. Percentage phase separation of the emul-
sion is calculated as follows [30]:
% phase separation of the emulsion = height of the oil
phase/(total height of emulsion sample × initial fraction
of oil in emulsion) × 100
Vaccination
Eight to ten week old C57BL/6 mice were purchased from
Taconic (Hudson, NY), vaccinated subcutaneously with
100 µg of HPV16 E7 peptide emulsified in 1:1 PBS:IFA
mixture and boosted two weeks later with another 100 µg
of HPV16 E7 peptide emulsified in 1:1 PBS:IFA mixture.
Seven days after the boost, four mice were sacrificed for
immune assays. For the tumor protection studies, eight
mice were challenged with 5 × 105 C3 cells ten days after
the boost. In the tumor protection studies using a subop-
timal dose of vaccine, 25 µg of HPV16 E7 peptide was
used to vaccinate the mice subcutaneously and the mice
were challenged with 106 C3 cells.
In vivo cytotoxicity assay
Spleens were harvested from eight to ten week old naïve
C57BL/6 mice and the splenocytes were used as target
cells for an in vivo cytotoxicity assay as previously
described[31]. The splenocytes were pooled and the red
blood cells lysed using ammonium chloride/potassium
(ACK) lysing buffer. The splenocytes were then washed
and incubated with 0.5 µg/ml E7 peptide or PSA peptide
Vortex, syringe-extrusion and homogenizer equipment used in this study Figure 1
Vortex, syringe-extrusion and homogenizer equipment used in this study. (a) VWR Mini Vortexer, (b) Glass 
syringes with 22-gauge connector reinforced with a steel bar, (c) Polytron PT2100 homogenizer
c b aJournal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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as an irrelevant peptide control at 37°C, 5% CO2 for 90
min with gentle agitation every 30 min. The splenocytes
were then washed three times and resuspended in
0.1%BSA in PBS. The E7 peptide-pulsed targets were
labeled with 10 mM carboxyfluoroscein succinimidyl
ester (CFSE) (Molecular Probes Invitrogen, Carlsbad, CA)
and the PSA peptide-pulsed targets labeled with 1 mM
CFSE at 37°C, 5% CO2 for 15 min. Ice-cold 10% IMDM
was used to stop the labeling reaction and the target cells
washed twice. The target cells were re-suspended at a final
concentration of 50 × 106 cells/ml and mixed at a 1:1
ratio. 200 µl of target cells were injected i.v into the retro-
orbital vein of vaccinated and control mice. The vacci-
nated and control mice were sacrificed the next day and
their spleens harvested. The red blood cells were lysed by
ACK lysing buffer and 5 × 106 cells used for FACS analysis
by gating on the CFSE positive splenocytes. The percent-
age specific lysis of the E7 peptide pulsed targets were
indicated by the loss of the CFSEhigh E7-pulsed population
relative to the control CFSElow PSA-pulsed population. %
specific lysis was calculated by the following formula :
% specific lysis = [(% irrelevant population-% relevant
population)/% irrelevant population] × 100
IFN-γ Elispot
Multiscreen-HTS IP plates (Millipore, Billerica, MA) were
washed with 50 µl of 70% ethanol, rinsed twice with 200
µl of sterile water and washed again with 200 µl sterile
PBS. IFN-γ capture antibody (R4-6A2) (BD Pharmingen,
San Diego, CA) was coated onto the plates at 5 µg/ml
overnight at 37°C. Capture antibody was discarded the
next day by flicking and the plates washed with 0.5% PBS-
TWEEN-20 (PBST) and then twice with 200 µl PBS. The
plates were blocked with 10% IMDM for 1 hr at 37°C.
Lymphocytes were plated at 2-fold serial dilutions along
with 10% IMDM containing 5 µg/ml IL-2 and 1 µg/ml E7
peptide or PSA peptide as an irrelevant peptide control.
After 48 hrs incubation at 37°C the cells were discarded
and the plates washed five times with 0.5% PBST and five
times with water. 100 µl of 5 µg/ml of biotinylated IFN-γ
(XMG1.2) (BD Pharmingen) was added to the wells and
incubated at 4°C overnight. Biotinylated anti-IFN-γ was
discarded by flicking and the plates washed six times with
0.05% PBST. 100 µl of 1 µg/ml horseradish peroxidase-
conjugated strepavidin (Sigma-Aldrich) in 0.05% PBST
and 1% BSA was added to the wells and incubated for 1 hr
at room temperature. The plates were washed three times
with 0.05% PBST and three times with PBS. The substrate,
3-amino-9-ethylcarbazole (AEC) (Sigma-Aldrich) was dis-
solved in dimethylformide (DMF) (Sigma-Aldrich) and
diluted in 0.1 M NaAc buffer pH 5.0. 5 µL of H2O2 was
added per 10 ml of AEC substrate solution just prior to
adding substrate to the wells. Substrate was allowed to
develop between 15 min to 60 min. Then the plates were
washed and allowed to dry. The spots were counted, aver-
aged and subtracted from the background spots counted
in the wells stimulated with the irrelevant PSA peptide.
This number was converted to the average number of IFN-
γ-secreting cells per 106 splenocytes present in the immu-
nized or control mice.
Tumor induction
C3 cells in the logarithmic growth phase were trypsinized,
washed and passed through a 70 µm cell strainer (BD Fal-
con) to obtain single-cell suspensions. The numbers of
viable cells were determined by trypan blue exclusion and
re-suspended in serum-free Hank's balanced salt solution
(HBSS) at the 5 × 106 cells/ml. Male C57BL/6 mice were
s.c. injected on the right flank with 5 × 105 cells using a 25-
gauge needle. Tumor growth was measured twice a week
in three dimensions. Tumor volume was calculated by
multiplying the length, width and height of the tumor.
Statistical analysis
Data were graphed used the Prizm 4 software Macintosh
(Graphpad Software Inc. San Diego, CA. The Student's t-
test (one-tailed) was carried out using the Prizm 4 soft-
ware. The Levene's test for the equality of variances was
carried out using the SPSS 12.0 software for Windows
(SPSS Inc. Chicago, IL).
Results
Physical stability of peptide emulsions
In order to demonstrate the integrity of the emulsions pre-
pared in this study, a droplet of the peptide emulsion was
dropped into a beaker of distilled water. Traditionally, an
emulsion is deemed properly prepared for vaccination if
the droplet retains its shape on the surface of the water.
The emulsions prepared using the vortex (Fig. 2a);
syringe-extrusion (Fig. 2b) or the homogenizer (Fig. 2c)
techniques were able to retain their integrity and did not
disperse upon contact with the water. The emulsion pre-
pared using the vortex technique appeared to be less vis-
cous but was still able to retain its integrity in the water-
drop test.
Emulsions are not in equilibrium and the different com-
ponents will separate over time. The measurement of the
separation of the oil phase from the rest of the emulsion
is another crude determinant of emulsion stability. The
emulsions prepared using syringe-extrusion, homoge-
nizer and vortex were aliquoted into 1 ml sample glass
vials, left to sit undisturbed, and the phase separation of
the oil from the emulsion measured over time. We saw no
appreciable differences in the phase separation of the
emulsions prepared using the different techniques (Fig.
3).Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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Water-drop test for emulsion stability Figure 2
Water-drop test for emulsion stability. Representative photographs of emulsion droplets prepared by vortex, syringe-
extrusion or homogenizer. (a) Emulsion was prepared using the vortex technique by vortexing the emulsion at 3,200 rpm for 
ten minutes in a 2 ml Eppendorf tube to reduce aeration. (b) Emulsion was pushed back and forth between two glass syringes 
connected by a 22-gauge connecter for ten minutes in the syringe-extrusion technique. (c) Emulsion was subjected to high-
speed homogenization for ten minutes with an attached blade at 30,000 rpm.
Phase separation Figure 3
Phase separation. Physical stability of W/O emulsions prepared using vortex, syringe-extrusion or homogenizer for ten min-
utes as determined by the separation of the oil phase from the emulsion. % phase separation is measured by taking the height 
of the oil phase/(total height of emulsion sample × initial fraction of oil in emulsion) × 100. The mean % phase separation and 
standard error of the mean of four emulsion samples prepared using vortex, syringe-extrusion or homogenizer is shown over 
time. Figure shown is representative of three experiments.Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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All three techniques of preparing emulsions induce 
immune responses
Eight to ten week old C57BL/6 mice were vaccinated and
boosted two weeks later with 100 µg of HPV16 E7 peptide
in order to test the vaccination efficacy of the peptide/IFA
emulsions prepared using the vortex, syringe-extrusion
and homogenizer techniques. A week after the boost, the
mice were sacrificed and their lymph nodes and spleno-
cytes harvested for immune assays (IFNγ-Elispot assay and
in vivo cytotoxicity assay respectively). From the IFNγ-Elis-
pot assay shown in figure 4, there was a statistically signif-
icant difference between the numbers of IFNγ-secreting
cells induced by the W/O emulsion peptide vaccine pre-
pared using the vortex versus the syringe-extrusion tech-
niques (p = 0.04). However there were no statistically
significant differences between the homogenizer tech-
nique with the vortex (p = 0.17) or with the syringe-extru-
sion technique (p = 0.17). Statistical analysis of the data
obtained from the in vivo cytotoxicity assay (Fig. 5)
showed that there were no statistically significant differ-
ences in the mean percentage specific lysis of the vacci-
nated mice from the vortex, syringe or homogenizer
groups. The variance in specific lysis values was found to
be statistically significantly greater for mice vaccinated
with the vortex compared to the syringe-extrusion (p =
0.03) and homogenizer (p = 0.05). Although our data do
not conclusively prove that the peptide-based vaccine
emulsions prepared using the vortex technique performs
worse than the syringe-extrusion group or the homoge-
nizer group, we did observe a trend that the immune
responses induced were often weaker. This was reflected
by the statistically lower numbers of IFNγ-secreting cells
induced in the Elispot assay and the lower median per-
centage specific lysis in the vortex group (median = 13%)
compared to the syringe-extrusion (median = 17%) or
homogenizer (median = 21%) in the in vivo cytotoxicity
assay.
All three techniques of preparing emulsions provided 
protection against tumor challenge
The immunological readouts of W/O emulsion vaccines
showed that there were no statistically significant differ-
ences in the mean percentage specific lysis among the
three techniques in the in vivo cytotoxicity assay but there
were fewer IFNγ-secreting cells induced by the peptide-
based vaccine emulsions prepared using the vortex com-
pared to the syringe-extrusion technique. We also
observed a trend that the vortex group would often per-
form slightly worse and the syringe-extrusion group had a
smaller variance in percentage specific lysis values than
the vortex or the homogenizer group. It is difficult to
ascertain what numbers of IFNγ-secreting cells or what
percentage specific lysis in the immunological experi-
ments would be enough to induce tumor protection in
vivo. Therefore we challenged the mice with a tumorigenic
dose of C3 tumor cells. A vaccination strategy administer-
ing two doses of 100 µg HPV-16 E7 peptide at a two-week
interval has been shown to mediate rejection of C3
tumors in C57BL/6 mice[29].
In the tumor challenge experiment shown in figure 6, all
of the vaccinated mice were protected from tumor chal-
lenge. Two injections of 100 µg of HPV-16 E7 peptide pro-
tects all the vaccinated mice and this peptide dose might
be at the plateau phase of the dose-response curve since
Daftarian et al. have successfully used the HPV-16 E7 pep-
tide at a dose of 50 µg [32]. We therefore reduced our vac-
cine dose to 25 µg of HPV-16 E7 peptide and increased the
tumor challenge dose to 106 C3 cells. This resulted in half
of the mice vaccinated in each group developing tumors
(Fig. 7). From the data obtained, the emulsion prepared
using the vortex technique provided the least protection
since the mice that did develop tumors had almost the
same size tumors compared to the control mice that did
not receive the HPV-16 E7 peptide. The mice vaccinated
with the emulsion prepared using the syringe extrusion
technique had smaller but not statistically significant
tumors compared to the vortex group (p = 0.21). The pep-
tide-based vaccine emulsion prepared using the homoge-
nizer technique was able to control the tumor growth the
best.
Discussion
The purpose of this study was to determine if there was
any immunological difference in the W/O emulsions pre-
pared using vortex, syringe-extrusion or homogenizer
techniques. In order to compare the techniques, we had to
ensure that stable emulsions were prepared properly using
the three techniques. Many investigators report not being
able to obtain a stable emulsion using the vortex although
it is a method that has been used to prepare peptide emul-
sions in the clinic[13,24,25,28]. In our own hands, we
have found that the size of the mixing vessel in which the
emulsion is prepared using the vortex made a major dif-
ference in its stability as determined by the ability of the
droplets to retain their shape when dropped into a beaker
of water. The vortex technique can potentially introduce
aeration into the emulsion system if the emulsification
was not carried out in a sufficiently small mixing vessel or
if there was too much splashing of the emulsion mixture
during the vortex process. Aeration must be avoided dur-
ing the process of emulsification because air introduces a
third phase into the emulsion system that destabilizes the
emulsion[33]. Even when the emulsions are prepared
using the conventional syringe-extrusion technique,
introducing air into the syringes would also result in an
unstable emulsion. Investigators should only use glass
syringes when preparing emulsions using the syringe-
extrusion technique as the rubber stopper can react chem-
ically with the mineral oils, potentially contaminating theJournal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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mixture and increasing the amount of physical pressure
needed to prepare the emulsions. Emulsion recovery
using the syringe-extrusion is approximately 50%–75%,
so volumes in excess to the amount required should be
prepared when using this method[22].
The integrity of the W/O emulsions is an important con-
sideration in vaccine efficacy because if the emulsion falls
apart immediately then the peptide antigens it carries
would be released and degraded rapidly, yielding an inef-
fective vaccine. Furthermore, it has been shown that the
pharmacokinetic difference between a T-cell tolerizing
peptide and a T-cell activating peptide was that the T-cell
tolerizing peptide spread through the body sixteen times
faster and was cleared two times quicker than the T-cell
activating peptide[17]. In the case of a peptide-based vac-
cine emulsion, if the emulsion is unstable, it will lead to
the rapid release of a high dose of peptide into the circu-
lating system. This can lead to activation-induced cell
death by the presence of an overwhelming amount of
antigen and tolerization rather than activation of the
immune system through presentation of the peptide on
non-professional antigen-presenting cells[18]. For immu-
nologists, the integrity of the vaccine emulsion is tested
IFN-γ ELISPOT Figure 4
IFN-γ ELISPOT. C57BL/6 mice (n = 4) were immunized with E7 peptide emulsified using vortex, syringe-extrusion or 
homogenizer for ten minutes and boosted two weeks later. One week after the boost, the mice were sacrificed and their 
lymph nodes harvested. E7peptide-specific response was measured by IFN-γ secreted after subtracting background IFN-γ 
secretion in the presence of PSA peptide as an irrelevant control. Control mice (n = 4) were vaccinated with PBS:IFA emulsion 
without peptide. The mean and standard error of the mean of each group is shown below. Figure shown is representative of 
three experiments. A Student's t-test (one-tailed) showed that there was a significant difference between the vortex versus the 
syringe-extrusion technique (p = 0.04) but no statistically significant differences between the homogenizer versus the vortex 
technique (p = 0.17) or the homogenizer technique versus the syringe-extrusion technique (p = 0.17).Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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using a subjective water-drop method where the emulsifi-
cation process is considered to be satisfactory if an emul-
sion droplet retains its integrity on the surface of a beaker
of water. The emulsions prepared using the vortex tech-
nique was shown in the water-drop test to deform slightly
on the surface of the water, but it was still stable enough
to maintain its spherical shape and its stability seemed
comparable to the other two techniques (Fig. 3) as deter-
mined by phase separation. Our data show that the vortex
emulsion was just as effective in inducing an immune
response that protected against tumor challenge at an
optimal vaccine dose (Fig. 6). There were statistically sig-
nificantly lower responses observed in the average num-
bers of IFNγ-secreting cells induced (Fig. 4) by the vortex
versus the syringe-extrusion technique (p = 0.04), but
there was no statistically significant difference in the mean
percentage specific lysis against the E7 peptide-pulsed tar-
gets (Fig. 5) among the mice that were vaccinated with
emulsions prepared using the vortex, syringe-extrusion or
homogenizer. We also observed that there was a greater
variance in the results obtained from the vortex group
compared to the syringe-extrusion group (Fig. 5). The
median value of the percentage specific lysis obtained
from mice vaccinated with the peptide vaccine prepared
by vortex was also lower compared to the syringe-extru-
sion or homogenizer (13% versus 17% versus 21%
respectively). The greater variance in percentage specific
lysis indicates that the vortex technique may not produce
emulsions as uniform as the syringe-extrusion method.
Decreased median values for the percentage specific lysis
obtained from mice vaccinated with the peptide vaccine
prepared by vortex may be the result of the non-random
in vivo cytotoxicity assay Figure 5
in vivo cytotoxicity assay. C57BL/6 mice (n = 4) were immunized with E7 peptide emulsified using vortex, syringe-extrusion 
or homogenizer for ten minutes and boosted two weeks later. Control mice (n = 4) were vaccinated with PBS:IFA emulsified 
by syringe-extrusion for ten minutes without peptide. One week after the boost, the mice were sacrificed and their spleens 
harvested. Figure is a box-plot showing the five-number summary (median, maximum, minimum, 25th and 75th quartile) of the % 
specific lysis of E7 peptide-pulsed target cells after subtracting background killing of irrelevant peptide control PSA peptide-
pulsed cells collected over five experiments. Median percentage specific lysis is 13% for the vortex group, 17% for the syringe-
extrusion group and 21% for the homogenizer group.Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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or incomplete distribution of the immunogen within the
emulsion prepared by the vortex technique. The clinical
implication of these findings is that the antigen-release
profile of emulsions prepared using the vortex technique
may be less consistent than the emulsions prepared using
the syringe-extrusion technique. This increases the varia-
bility of the vaccine in its induction of the immune
response. In some cases, it would induce a significantly
higher response and in others, it results in an inferior
immune response compared to the syringe-extrusion as
reflected by the distribution of percentage specific lysis
values in the in vivo cytotoxicity assay compared with the
other two techniques. Our tumor challenge experiments
were carried out an optimal dose setting, which accounts
for why all the vaccinated mice were able to successfully
reject the tumor challenge regardless of how the vaccine
was emulsified. In the suboptimal dose tumor challenge
experiment (Fig. 7), half of the mice vaccinated with the
vortex, syringe-extrusion and homogenizer were still able
to successfully reject the tumor. However, in the other half
that did develop tumors, it was shown that the mice vac-
cinated with the emulsion prepared using the vortex tech-
nique had the largest tumors and the homogenizer group
had the smallest tumors. In the clinical trial settings where
the optimal dose might be unknown and where the suc-
cess of the trial hinges on inducing the maximum
immune responses, investigators might want to consider
using the syringe-extrusion method or the homogenizer
method instead of the vortex to prepare emulsions.
Despite the fact that the syringe-extrusion method is more
tedious, clinical vaccines are not usually produced for
large numbers of patients daily and it would not be that
Tumor challenge in optimal vaccine dose conditions Figure 6
Tumor challenge in optimal vaccine dose conditions. C3 challenge of vaccinated and control mice (n = 8) with E7-
expressing C3 cells. C57BL/6 mice (n = 8) were immunized with 100 µg E7 peptide emulsified using vortex, syringe-extrusion 
or homogenizer for ten minutes and boosted two weeks later. Ten days after the boost, the mice were challenged with 5 × 105 
C3 cells. The control mice developed tumors but all the vaccinated mice successfully rejected the C3 cells. The mean tumor 
volume and standard error of the mean of each group of mice over time is shown. Figure shown is representative of four 
experiments.Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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difficult to push the emulsion through a small bore 22-
gauge connector as long as it is reinforced with a steel bar.
The high-speed homogenizer is the most rapid and con-
venient method amongst the three techniques compared
for preparing W/O emulsions. The model of homogenizer
that we have used in our experiment is unsuitable for clin-
ical studies because the homogenizer tip cannot be
removed for sterilization but it is the ideal method for
investigators carrying out animal studies where large
batches of emulsion may need to be made. Omni interna-
tional manufactures a homogenization system, Omni
Tip™ Tissue Homogenizing Kit that features a plastic, ster-
ilizable tip (TH115-PCRD) with a sealed 15 ml tube that
could be amenable to clinical use, although this homoge-
nizer system has not been used in our comparison studies.
The depot mechanism by which W/O emulsions exert
their adjuvant effect is dependent on the ability of the IFA
to form aggregates that can be transported into the lym-
phoid organs where they will form a stable depot that
slowly releases antigen over time[20,21]. This allows the
antigen to be processed and presented in the optimal
immunological milieu with professional antigen-present-
ing cells that express co-stimulatory molecules and pro-
duce cytokines. Small depots of the emulsions were
observed in the draining lymph nodes in the mice that
Tumor challenge in suboptimal vaccine dose conditions Figure 7
Tumor challenge in suboptimal vaccine dose conditions. C3 challenge of vaccinated and control mice (n = 8) with E7-
expressing C3 cells. C57BL/6 mice (n = 8) were immunized with 25 µg E7 peptide emulsified using vortex, syringe-extrusion or 
homogenizer for ten minutes and boosted two weeks later. Ten days after the boost, the mice were challenged with 106 C3 
cells. The control mice developed tumors. Four out of eight of each group of the vaccinated mice successfully rejected the C3 
cells. Figure shown is the tumor growth over time of the four mice from each of the vaccinated groups that did develop tumors 
compared to the control mice. The mean tumor volume and standard error of the mean of each group of mice is shown. Fig-
ure shown is representative of two experiments. Using a Student's t-test (one-tailed), the vortex did not differ statistically sig-
nificant from the syringe-extrusion technique (p = 0.21), but the homogenizer was statistically significantly different from the 
vortex (p = 0.02) and the syringe-extrusion technique (p = 0.02).Journal of Translational Medicine 2006, 4:42 http://www.translational-medicine.com/content/4/1/42
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were immunized using syringe-extrusion, vortex and
homogenizer (results not shown). All three methods pro-
duced emulsions that were able to form aggregates that
could be transported into the draining lymph nodes and
stably release antigens over time in the environment opti-
mum for the induction of immune response[18] and all
three methods can be used for the preparation of peptide-
based vaccine emulsions. We have found no differences in
the ability of the peptide-based vaccine emulsions to pro-
tect against a tumor challenge at an optimal vaccine dose
but at suboptimal vaccine dose, the vortex technique was
the least able to control tumor growth. The vortex tech-
nique induced statistically significantly less IFNγ-secreting
cells compared to the syringe technique and had higher
variability in the percentage specific lysis in the in vivo
cytotoxicity assay. This leads us to advise investigators to
use the syringe-extrusion technique or homogenizer tech-
nique for emulsifying peptide vaccines in clinical trials.
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